A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2a, Proof-of-Concept Study of ASP8302 in Subjects With Underactive Bladder
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs ASP 8302 (Primary)
- Indications Bladder dysfunction
- Focus Proof of concept; Therapeutic Use
- Sponsors Astellas Pharma Europe Ltd
- 21 Aug 2019 Planned number of patients changed to 163.
- 05 Aug 2019 Planned number of patients changed from 125 to 130.
- 05 Aug 2019 Planned End Date changed from 1 Nov 2019 to 1 Jun 2020.